{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:12:26Z","timestamp":1785363146657,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.lungcan.2018.11.002","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T11:48:19Z","timestamp":1541418499000},"page":"156-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients"],"prefix":"10.1016","volume":"126","author":[{"given":"Satoshi","family":"Anai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Yoneshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Otsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12 Pt 1","key":"10.1016\/j.lungcan.2018.11.002_bib0005","first-page":"5857","article-title":"Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage","volume":"44","author":"Ross","year":"1984","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2018.11.002_bib0010","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.bjc.6604480","article-title":"Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer","volume":"99","author":"Baka","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2018.11.002_bib0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2018.11.002_bib0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/sj.bjc.6603810","article-title":"Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702","volume":"97","author":"Okamoto","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.lungcan.2018.11.002_bib0025","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2018.11.002_bib0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"Pt 1","key":"10.1016\/j.lungcan.2018.11.002_bib0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/bj3030233","article-title":"Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation","volume":"303","author":"Senafi","year":"1994","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.lungcan.2018.11.002_bib0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0925-4439(98)00013-1","article-title":"Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert\u2019s syndrome and Crigler-Najjar syndrome type II","volume":"1406","author":"Yamamoto","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"issue":"4 Pt 2","key":"10.1016\/j.lungcan.2018.11.002_bib0045","first-page":"596","article-title":"Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan","volume":"29","author":"Innocenti","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.lungcan.2018.11.002_bib0050","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1124\/dmd.107.017806","article-title":"Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism","volume":"35","author":"Zhang","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"24","key":"10.1016\/j.lungcan.2018.11.002_bib0055","first-page":"6921","article-title":"Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis","volume":"60","author":"Ando","year":"2000","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2018.11.002_bib0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/1759-7714.12360","article-title":"Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: results of Lung Oncology Group in Kyusyu (LOGIK1004B)","volume":"7","author":"Fukuda","year":"2016","journal-title":"Thorac. Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2018.11.002_bib0065","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan","volume":"22","author":"Innocenti","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2018.11.002_bib0070","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.23370","article-title":"UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma","volume":"112","author":"Liu","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2018.11.002_bib0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/JTO.0b013e318200e4e8","article-title":"Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia","volume":"6","author":"Nakamura","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2018.11.002_bib0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/dmd.31.5.589","article-title":"Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1","volume":"31","author":"Watanabe","year":"2003","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.lungcan.2018.11.002_bib0085","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1124\/dmd.106.012732","article-title":"UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics","volume":"35","author":"Wen","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.lungcan.2018.11.002_bib0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/FPC.0b013e32832e0e7f","article-title":"Etoposide pathway","volume":"19","author":"Yang","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"issue":"1","key":"10.1016\/j.lungcan.2018.11.002_bib0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2003-06-2105","article-title":"Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia","volume":"103","author":"Kishi","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lungcan.2018.11.002_bib0100","first-page":"529","article-title":"Improvements in creatinine methodology: a critical assessment","volume":"32","author":"Blijenberg","year":"1994","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"issue":"7","key":"10.1016\/j.lungcan.2018.11.002_bib0105","first-page":"296","article-title":"Comparison of Jaffe rate assay and enzymatic method for the measurement of creatinine clearance","volume":"38","author":"Horio","year":"1996","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"9\u201310","key":"10.1016\/j.lungcan.2018.11.002_bib0110","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.clinbiochem.2007.03.007","article-title":"Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism","volume":"40","author":"Baudhuin","year":"2007","journal-title":"Clin. Biochem."},{"issue":"3","key":"10.1016\/j.lungcan.2018.11.002_bib0115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software\u2019 EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.lungcan.2018.11.002_bib0120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/oxfordjournals.annonc.a059180","article-title":"Etoposide: twenty years later","volume":"6","author":"Hainsworth","year":"1995","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2018.11.002_bib0125","first-page":"7777","article-title":"Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase","volume":"61","author":"Kagan","year":"2001","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2018.11.002_bib0130","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-03-0221","article-title":"Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide","volume":"10","author":"Zheng","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2018.11.002_bib0135","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0090-9556(24)02983-0","article-title":"Kinetics and regulation of cytochrome P450-mediated etoposide metabolism","volume":"32","author":"Zhuo","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.lungcan.2018.11.002_bib0140","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/tx400205n","article-title":"Etoposide catechol is an oxidizable topoisomerase II poison","volume":"26","author":"Jacob","year":"2013","journal-title":"Chem. Res. Toxicol."},{"issue":"25","key":"10.1016\/j.lungcan.2018.11.002_bib0145","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1021\/bi200438m","article-title":"Etoposide quinone is a redox-dependent topoisomerase II poison","volume":"50","author":"Jacob","year":"2011","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.lungcan.2018.11.002_bib0150","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/toxsci\/kfv182","article-title":"Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells","volume":"148","author":"Kwon","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.lungcan.2018.11.002_bib0155","doi-asserted-by":"crossref","first-page":"34064","DOI":"10.1038\/srep34064","article-title":"Etoposide induced cytotoxicity mediated by ROS and ERK in human kidney proximal tubule cells","volume":"6","author":"Shin","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2018.11.002_bib0160","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2018.11.002_bib0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40262-016-0450-z","article-title":"Genotypes affecting the pharmacokinetics of anticancer drugs","volume":"56","author":"Bertholee","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.lungcan.2018.11.002_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101902","article-title":"Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection","volume":"9","author":"Kidera","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.lungcan.2018.11.002_bib0175","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1248\/bpb.b16-00473","article-title":"Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer","volume":"39","author":"Miyoshi","year":"2016","journal-title":"Biol. Pharm. Bull."},{"issue":"7","key":"10.1016\/j.lungcan.2018.11.002_bib0180","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","article-title":"Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin","volume":"36","author":"Motwani","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2018.11.002_bib0185","first-page":"988","article-title":"Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump","volume":"56","author":"Jedlitschky","year":"1996","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2018.11.002_bib0190","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/1078-0432.CCR-09-1321","article-title":"P-glycoprotein (P-gp\/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide","volume":"16","author":"Lagas","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"49","key":"10.1016\/j.lungcan.2018.11.002_bib0195","doi-asserted-by":"crossref","first-page":"46400","DOI":"10.1074\/jbc.M107041200","article-title":"Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3)","volume":"276","author":"Zelcer","year":"2001","journal-title":"J. Biol. Chem."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218306299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218306299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:45:42Z","timestamp":1775259942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218306299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":39,"alternative-id":["S0169500218306299"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.11.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}